Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 11/20 | 0.51 |
| ▸ | ALOX5AP | P20292 | 9/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.43 |
| ▸ | TDO2 | P48775 | 2/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1409516 | 0.82 | FEN1 (0.54) | FEN1ALOX5APTDO2PIK3CDMKNK1 | |
| SCHEMBL19154379 | 0.82 | PTGS2 (0.45) | FEN1ALOX5APABL1TDO2CYP3A4 | |
| SCHEMBL4504756 | 0.79 | ABL1 (0.68) | FEN1ALOX5APABL1EIF2AK3TDO2 | |
| SCHEMBL4502041 | 0.79 | EIF2AK3 (0.55) | FEN1ALOX5APABL1EIF2AK3TDO2 | |
| SCHEMBL20929592 | 0.78 | ALOX5AP (0.38) | FEN1ALOX5APABL1CYP3A4CYP2A6 | |
| SCHEMBL13310790 | 0.77 | CYP3A4 (0.37) | FEN1ALOX5APABL1CYP3A4CYP2A6 | |
| SCHEMBL803253 | 0.77 | PTGS2 (0.38) | FEN1ALOX5AP | |
| SCHEMBL13310785 | 0.77 | ALOX5AP (0.38) | FEN1ALOX5APABL1CYP3A4CYP2A6 | |
| SCHEMBL15681345 | 0.76 | CYP3A4 (0.40) | FEN1ALOX5APALDH1A1CYP3A4 | |
| SCHEMBL4502030 | 0.76 | PIK3CD (0.46) | FEN1ALOX5APABL1TDO2NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211913-B2 | 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20090149503-A1 | NEW 5-ARYL PYRIDINES AS 11-BETA INHIBITORS FOR THE TREATMENT OF DIABETES | AMREIN KURT | 2009-06-11 | — | — | US | disclosed |
| US-7528159-B2 | 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2009-05-05 | — | — | US | disclosed |
| EP-1789041-B1 | ARYL-PYRIDINE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-07-09 | — | — | EP | disclosed |
| EP-1789041-A2 | ARYL-PYRIDINE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | F. Hoffmann-Roche AG (CH) | 2007-05-30 | — | — | EP | disclosed |
| US-20060025455-A1 | New 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. | 2006-02-02 | — | — | US | disclosed |
| WO-2006010546-A2 | ARYL-PYRIDINE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | F. HOFFMAN-LA ROCHE AG (CH) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149503-A1 | NEW 5-ARYL PYRIDINES AS 11-BETA INHIBITORS FOR THE TREATMENT OF DIABETES | GPR119, CYP4B1, SLC5A1 | FEN1 3489/4885ALOX5AP 1045/4885ABL1 821/4885 |
| US-20060025455-A1 | New 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes | GPR119, CYP4B1, SLC5A1 | FEN1 3489/4885ALOX5AP 1045/4885ABL1 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.